MX2018009913A - Aglutinantes max como moduladores myc y sus usos. - Google Patents

Aglutinantes max como moduladores myc y sus usos.

Info

Publication number
MX2018009913A
MX2018009913A MX2018009913A MX2018009913A MX2018009913A MX 2018009913 A MX2018009913 A MX 2018009913A MX 2018009913 A MX2018009913 A MX 2018009913A MX 2018009913 A MX2018009913 A MX 2018009913A MX 2018009913 A MX2018009913 A MX 2018009913A
Authority
MX
Mexico
Prior art keywords
formula
myc
binders
max
modulators
Prior art date
Application number
MX2018009913A
Other languages
English (en)
Inventor
Chen Andrew
N Koehler Angela
Stefan Eric
Caballero Francisco
Vijith Neel Dylan
L Evans Helen
B Struntz Nicholas
Original Assignee
Massachusetts Inst Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology filed Critical Massachusetts Inst Technology
Publication of MX2018009913A publication Critical patent/MX2018009913A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La presente descripcion proporciona compuestos de la Formula (I'), Formula (I), Formula (II), Formula (II-A), Formula (III), y Formula (IV); los compuestos descritos en la presente son aglutinantes MAX y/o moduladores de Myc, Mad, o Mxi1 (por ejemplo, inhibidores de Myc, Mad, o Mxi1), y pueden ser utiles para el tratamiento de un sujeto con una enfermedad asociada con Myc tal como enfermedades proliferativas (por ejemplo, cancer); tambien se proporcionan en la presente divulgacion composiciones y kits farmaceuticos que incluyen los compuestos descritos en este documento, asi como metodos de uso y usos de los compuestos, composiciones y kits; (ver fórmula).
MX2018009913A 2016-02-16 2017-02-16 Aglutinantes max como moduladores myc y sus usos. MX2018009913A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662295996P 2016-02-16 2016-02-16
PCT/US2017/018162 WO2017143059A1 (en) 2016-02-16 2017-02-16 Max binders as myc modulators and uses thereof

Publications (1)

Publication Number Publication Date
MX2018009913A true MX2018009913A (es) 2018-11-29

Family

ID=58191662

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018009913A MX2018009913A (es) 2016-02-16 2017-02-16 Aglutinantes max como moduladores myc y sus usos.

Country Status (11)

Country Link
US (2) US10106555B2 (es)
EP (1) EP3416950A1 (es)
JP (1) JP2019505548A (es)
KR (1) KR20180107261A (es)
CN (1) CN109071456A (es)
AU (1) AU2017221422A1 (es)
BR (1) BR112018016133A2 (es)
CA (1) CA3012846A1 (es)
MX (1) MX2018009913A (es)
RU (1) RU2018132559A (es)
WO (1) WO2017143059A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3012846A1 (en) 2016-02-16 2017-08-24 Massachusetts Institute Of Technology Max binders as myc modulators and uses thereof
JP2021531253A (ja) * 2018-07-09 2021-11-18 ザ スクリプス リサーチ インスティテュート Ｍｙｃ阻害のための改良された化合物
CN111274691A (zh) * 2020-01-16 2020-06-12 西安交通大学 一种分析预测max相材料可形成能力的方法
WO2021195360A1 (en) 2020-03-27 2021-09-30 Landos Biopharma, Inc. Plxdc2 ligands
CA3208313A1 (en) 2021-01-13 2022-07-21 Monte Rosa Therapeutics Ag Isoindolinone compounds
CN116908444B (zh) * 2023-09-13 2023-12-19 中国医学科学院北京协和医院 血浆max自身抗体在晚期非小细胞肺癌pd-1单抗联合化疗治疗预后预测中的应用

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02191695A (ja) 1989-01-20 1990-07-27 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02194085A (ja) 1989-01-24 1990-07-31 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02196887A (ja) 1989-01-26 1990-08-03 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02208392A (ja) 1989-02-08 1990-08-17 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02222488A (ja) 1989-02-23 1990-09-05 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02227489A (ja) 1989-02-28 1990-09-10 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02227490A (ja) 1989-02-28 1990-09-10 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02227491A (ja) 1989-03-01 1990-09-10 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02242882A (ja) 1989-03-16 1990-09-27 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02247280A (ja) 1989-03-20 1990-10-03 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02247282A (ja) 1989-03-22 1990-10-03 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02255794A (ja) 1989-03-29 1990-10-16 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02255793A (ja) 1989-03-30 1990-10-16 Dainippon Ink & Chem Inc 強誘電性液晶組成物
US5965574A (en) 1996-08-13 1999-10-12 Chen; Yuhpyng Liang Heteroaryl amines as novel acetylcholinesterase inhibitors
JPH08231541A (ja) 1995-03-01 1996-09-10 Nippon Soda Co Ltd イミダゾリン誘導体および除草剤
AU6331099A (en) 1998-09-30 2000-04-17 Roche Diagnostics Gmbh Thiazolidine derivatives for the treatment and prevention of metabolic bone disorders
WO2000023451A1 (en) 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
JP4224566B2 (ja) 2000-12-18 2009-02-18 株式会社医薬分子設計研究所 炎症性サイトカイン産生遊離抑制剤
US6452014B1 (en) 2000-12-22 2002-09-17 Geron Corporation Telomerase inhibitors and methods of their use
JP2003057783A (ja) 2001-08-21 2003-02-26 Konica Corp 銀色調を改良した光熱写真画像形成材料
JP2003075955A (ja) 2001-09-03 2003-03-12 Konica Corp 銀色調を改良した光熱写真画像形成材料
JP2003075957A (ja) 2001-09-07 2003-03-12 Konica Corp スケイル模様のない光熱写真画像形成材料
HUP0401492A3 (en) 2001-09-14 2008-05-28 Novo Nordisk As Novel ligands for the hisb10 zn2+ sites of r-state insulin hexa
US20050042674A9 (en) 2002-02-21 2005-02-24 Lin Yu Common ligand mimics: thiazolidinediones and rhodanines
GB2387172A (en) 2002-03-28 2003-10-08 Pantherix Ltd [(Aryl-/arylthio-)aryl]methylene substituted azole & azine derivatives and their therapeutic use as antibacterials
CA2483771A1 (en) 2002-04-30 2004-03-25 Merck & Co., Inc. Aryl-link-aryl substituted thiazolidine-dione and oxazolidine-dione as sodium channel blockers
JP4211433B2 (ja) 2002-08-14 2009-01-21 三菱化学株式会社 有機金属錯体、発光色素、有機電界発光素子材料および有機電界発光素子
WO2004080989A1 (ja) 2003-03-10 2004-09-23 Sumitomo Chemical Company Limited フラン化合物の製造方法
US7777051B2 (en) 2003-05-13 2010-08-17 Icagen, Inc. Asymmetric benzimidazoles and related compounds as potassium channel modulators
US20060074124A1 (en) 2003-09-12 2006-04-06 Andrew Napper Methods of treating a disorder
WO2005026112A2 (en) 2003-09-12 2005-03-24 Elixir Pharmaceuticals, Inc. Methods of treating a disorder
US7842941B2 (en) 2003-10-06 2010-11-30 Sumitomo Chemical Company, Limited Aromatic compound
EP1768694A1 (en) 2004-07-09 2007-04-04 Novo Nordisk A/S Phamaceutical preparations comprising insulin
JP2006084592A (ja) 2004-09-14 2006-03-30 Fuji Photo Film Co Ltd 感光性組成物
DE602005018911D1 (de) 2005-07-20 2010-03-04 Aventis Pharma Sa 1,4-Dihydropyridine-kondensierte Heterocyclen Verfahren zu deren Herstellung sowie Verwendung und Zusammensetzungen dergleichen
WO2007047604A2 (en) 2005-10-18 2007-04-26 Elixir Pharmaceuticals, Inc. Sirt1 inhibition
JP4931434B2 (ja) 2006-02-14 2012-05-16 株式会社ダイセル アミノ基含有アダマンタン誘導体とその製造方法
WO2007146712A2 (en) 2006-06-09 2007-12-21 Kemia, Inc. Therapy using cytokine inhibitors
US20100009969A1 (en) 2006-07-27 2010-01-14 Ucb Pharma, S.A. Fused Oxazoles & Thiazoles As Histamine H3- Receptor Ligands
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
US20100292188A1 (en) 2008-01-24 2010-11-18 Ucb Pharma S.A. Compounds Comprising A Cyclobutoxy Group
EP2255201B1 (en) 2008-02-28 2014-08-06 Life Technologies Corporation Fluorescence polarization herg assay
CA2743134A1 (en) 2008-11-10 2010-05-14 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
WO2010058402A1 (en) 2008-11-20 2010-05-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Novel anti-biofilm agents
US20120040916A1 (en) 2008-12-22 2012-02-16 Massachusetts Institute Of Technology Molecular inhibitors of the wnt/beta-catenin pathway
JP5046213B2 (ja) 2009-03-12 2012-10-10 独立行政法人科学技術振興機構 光学活性アルコール化合物の製法
JP2013511562A (ja) 2009-11-24 2013-04-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎阻害化合物
KR101851130B1 (ko) 2009-12-04 2018-04-23 센화 바이오사이언시즈 인코포레이티드 Ｃｋ2 억제제로서 피라졸로피리미딘 및 관련된 헤테로사이클
US9133186B2 (en) 2010-09-10 2015-09-15 Shionogi & Co., Ltd. Hetero ring-fused imidazole derivative having AMPK activating effect
WO2012153780A1 (ja) 2011-05-11 2012-11-15 出光興産株式会社 新規化合物、有機エレクトロルミネッセンス素子用材料及び有機エレクトロルミネッセンス素子
CN103649067A (zh) 2011-09-13 2014-03-19 出光兴产株式会社 稠合杂芳香族衍生物、有机电致发光元件用材料及使用其的有机电致发光元件
WO2013177241A1 (en) 2012-05-22 2013-11-28 Trustees Of Dartmouth College Method for synthesizing cycloalkanyl(b}indoles, cycloalkanyl(b) benzofurans, cycloalkanyl(b)benzothiophenes, compounds and methods of use
BR112015012454B1 (pt) * 2012-12-07 2022-07-05 Vertex Pharmaceuticals Incorporated Compostos inibidores de atr quinase, seu uso e composição farmacêutica compreendendo os mesmos
EP2985278B1 (en) 2013-02-28 2020-01-22 Sumitomo Chemical Company, Limited Fused heterocyclic compound and pest control applications thereof
US8901164B2 (en) * 2013-03-07 2014-12-02 University Of Maryland, Baltimore Amphipathic and other double-sided alpha-helix mimetics based on a 1,2-diphenylacetylene scaffold
MX367420B (es) 2013-03-14 2019-08-21 Convergene Llc Metodos y composiciones para inhibicion de proteinas que contienen bromodominio.
US9242944B2 (en) * 2013-03-27 2016-01-26 University Of Maryland, Baltimore Potent analogues of the C-Myc inhibitor 10074-G5 with improved cell permeability
US11066398B2 (en) * 2013-12-11 2021-07-20 The Scripps Research Institute Small molecule c-Myc inhibitors
WO2016094688A1 (en) 2014-12-10 2016-06-16 Massachusetts Institute Of Technology Fused 1,3-azole derivatives useful for the treatment of proliferative diseases
CA3012846A1 (en) 2016-02-16 2017-08-24 Massachusetts Institute Of Technology Max binders as myc modulators and uses thereof

Also Published As

Publication number Publication date
US20170233405A1 (en) 2017-08-17
BR112018016133A2 (pt) 2019-01-02
US20190144466A1 (en) 2019-05-16
US10106555B2 (en) 2018-10-23
JP2019505548A (ja) 2019-02-28
WO2017143059A1 (en) 2017-08-24
EP3416950A1 (en) 2018-12-26
AU2017221422A1 (en) 2018-08-16
KR20180107261A (ko) 2018-10-01
CA3012846A1 (en) 2017-08-24
US10865213B2 (en) 2020-12-15
CN109071456A (zh) 2018-12-21
RU2018132559A (ru) 2020-03-17

Similar Documents

Publication Publication Date Title
MX2018009913A (es) Aglutinantes max como moduladores myc y sus usos.
PH12019501350A1 (en) Amino-triazolopyridine compounds and their use in treating cancer
AU2018236742B2 (en) Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
MX2018009633A (es) Inhibidor de indoleamina-2,3-dioxigenasa (ido).
MY196582A (en) PD-1/PD-L1 Inhibitors
MX2018009496A (es) Degradadores selectivos del receptor de estrogeno y sus usos.
MX2022000789A (es) Compuestos heterociclicos como inmunomoduladores.
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
NZ754051A (en) Novel antibodies and uses thereof
MX2022005290A (es) Compuestos heterociclicos como inmunomoduladores.
PH12018501226A1 (en) Methods for treating huntingtons disease
WO2017176957A8 (en) Mdm2 protein degraders
WO2018049152A8 (en) Pyrazolopyrimidine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
MY197635A (en) Benzooxazole derivatives as immunomodulators
MA40074A (fr) Composés liant ras multivalents
MX2019014514A (es) Compuestos para tratar la enfermedad de huntington.
MX2018001387A (es) Anticuerpo de dominio simple y proteinas derivadas del mismo contra ligando de muerte programada (pdl1).
PH12018502535A1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
WO2016130920A3 (en) Lrrk2 inhibitors and methods of making and using the same
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
EA200870415A1 (ru) Хиназолины для ингибирования pdk 1
WO2015108998A8 (en) Cartilage targeting agents and their use
WO2019035864A8 (en) PYRUVATE KINASE ACTIVATORS FOR USE IN THE TREATMENT OF BLOOD DISORDERS
PH12021550124A1 (en) Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same
MY192861A (en) 1, 3, 4-thiadiazole compounds and their use in treating cancer